Article
cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution.
Clinical cancer research : an official journal of the American Association for Cancer Research - 2 May 2022
Li Shuo, Zeng Weihua, Ni Xiaohui, Zhou Yonggang, Stackpole Mary L, Noor Zorawar S, Yuan Zuyang, Neal Adam, Memarzadeh Sanaz, Garon Edward B, Dubinett Steven M, Li Wenyuan, Zhou Xianghong Jasmine
Abstract excerpt
PURPOSE: Cell-free DNA (cfDNA) offers a noninvasive approach to monitor cancer. Here we develop a method using whole-exome sequencing (WES) of cfDNA for simultaneously monitoring the full spectrum of cancer treatment outcomes, including minimal residual disease (MRD), recurrence, evolution, and second primary cancers. EXPERIMENTAL DESIGN: Three simulation datasets were generated from 26 patients with cancer to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.